Physician profile
Mary E Nelson
NPI 1518165745
$1,680.00
in general payments reported to CMS, 2019-2025
23 companies · $554 in 2025
The $554 reported for 2025 was more than what 75% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $155 · 2020: $16.20 · 2023: $43.87 · 2024: $911 · 2025: $554.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,509.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,508.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $305.09 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $218.74 | 2024-2025 | |
| Abbvie INC. | $214.25 | 2023-2024 | |
| Vanda Pharmaceuticals INC. | $146.70 | 2024-2025 | Fanapt |
| Insmed, INC. | $115.70 | 2019 | |
| Glaxosmithkline, LLC. | $112.33 | 2024-2025 | Arexvy, Shingrix, Bexsero |
| Astrazeneca Pharmaceuticals LP | $109.66 | 2024-2025 | Airsupra, Farxiga, Breztri |
| E.R. Squibb & Sons, L.L.C. | $61.84 | 2025 | Eliquis |
| Abbott Laboratories | $56.70 | 2024 | Freestyle Libre 3 |
| Exact Sciences Corporation | $56.19 | 2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $45.35 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Janssen Pharmaceuticals, INC | $35.43 | 2019-2020 | |
| Amgen INC. | $28.68 | 2024 | Otezla, Repatha |
| Novartis Pharmaceuticals Corporation | $20.27 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $19.89 | 2025 | Caplyta |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $18.76 | 2024 | (Ck7) Extended Holter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.88 | 2024 | Jardiance |
| Dexcom, INC. | $17.80 | 2023 | Dexcom G6 Transmitter |
| Seqirus USA INC | $17.66 | 2025 | Flucelvax, Fluad |
| Sanofi Pasteur INC. | $16.35 | 2025 | |
| Phathom Pharmaceuticals, INC. | $16.09 | 2025 | Voquezna |
| Kyowa Kirin, INC. | $14.81 | 2024 | Crysvita |
| Bayer Healthcare Pharmaceuticals INC. | $13.83 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Nelson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.